Aug 6, 2025 08:30AM RenovoRx expands commercial reach for RenovoCath device to 13 centers

Jul 28, 2025 08:31AM RenovoRx starts multi-center registry study for cancer device

Jun 5, 2025 05:02AM RenovoRx Inc. (RNXT) PT Raised to $11.50 at Ascendiant Capital

May 15, 2025 05:54PM RenovoRx, Inc. (RNXT) Tops Q1 EPS by 1c

Apr 29, 2025 08:35AM RenovoRx (RNXT): Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 16, 2025 08:36AM RenovoRx (RNXT) Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community

Apr 4, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on RenovoRx Inc. (RNXT)

Apr 1, 2025 08:30AM RenovoRx (RNXT) Reports Initial Revenues from RenovoCath Commercialization, Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Mar 26, 2025 08:01AM RenovoRx (RNXT) Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Feb 6, 2025 04:05PM RenovoRx (RNXT) Announces Proposed Share Offering

Dec 5, 2024 08:01AM RenovoRx (RNXT) Receives First Purchase Orders for its FDA-Cleared RenovoCath Delivery System

Sep 25, 2024 08:32AM RenovoRx (RNXT) Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Jul 31, 2024 08:33AM RenovoRx (RNXT) Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist

Jun 17, 2024 03:25AM Ascendiant Capital Starts RenovoRx Inc. (RNXT) at Buy

Jun 10, 2024 08:33AM RenovoRx (RNXT) Appoints Ryan Witt as SVP of Head of Corporate Strategy and Partnerships